Nanoviricides Inc (NNVC)
2.08
-0.15
(-6.73%)
USD |
NYAM |
May 17, 16:00
2.08
0.00 (0.00%)
After-Hours: 20:00
Nanoviricides Cash from Financing (Quarterly): 0.00 for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | -0.0238M |
| September 30, 2022 | -0.071M |
| June 30, 2022 | -0.0327M |
| March 31, 2022 | -0.0693M |
| December 31, 2021 | -0.0614M |
| September 30, 2021 | -0.0713M |
| June 30, 2021 | -0.0705M |
| March 31, 2021 | 6.052M |
| December 31, 2020 | -1.075M |
| September 30, 2020 | 10.35M |
| June 30, 2020 | 9.316M |
| March 31, 2020 | 7.795M |
| December 31, 2019 | 0.9589M |
| September 30, 2019 | -0.2421M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 2.35M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | -1.00M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.061M |
| September 30, 2014 | 6.682M |
| June 30, 2014 | 5.00M |
| March 31, 2014 | 19.44M |
| December 31, 2013 | 0.025M |
| September 30, 2013 | 9.876M |
| June 30, 2013 | -0.0975M |
| March 31, 2013 | 4.286M |
| December 31, 2012 | 2.322M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 2.187M |
| March 31, 2012 | 2.316M |
| December 31, 2011 | 2.464M |
| September 30, 2011 | 2.361M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.075M
Minimum
Dec 2020
10.35M
Maximum
Sep 2020
1.724M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 0.115M |
| Enanta Pharmaceuticals Inc | -6.414M |
| GlycoMimetics Inc | 0.0049M |
| FibroGen Inc | -0.165M |
| Corvus Pharmaceuticals Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.719M |
| Cash from Investing (Quarterly) | -0.0055M |
| Free Cash Flow | -6.203M |
| Free Cash Flow Per Share (Quarterly) | -0.1468 |
| Free Cash Flow Yield | -25.51% |